Treatment outcomes of erlotinib plus gemcitabine as late-line chemotherapy in unresectable pancreatic cancer
ConclusionsBenefits of erlotinib plus gemcitabine as late-line chemotherapy were limited, particularly with respect to PFS. Development of more effective third-line treatment options is desirable in the future.
Source: Japanese Journal of Clinical Oncology - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Japan Health | Pancreas | Pancreatic Cancer | Pneumonia | Study | Tarceva